Gibson Dunn advises Damora Therapeutics on sale to Galecto and Galecto's $2.85 billion private placement

The Sponsor

Loading page...

Gibson Dunn advises Damora Therapeutics on sale to Galecto and Galecto's $2.85 billion private placement | The Sponsor - The Sponsor